{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T04:16:04Z","timestamp":1692850564023},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00393-017-0325-1","type":"journal-article","created":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T08:42:29Z","timestamp":1495528949000},"page":"12-20","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Off-label-Biologikatherapie bei Patienten mit Gro\u00dfgef\u00e4\u00dfvaskulitiden und\/oder Polymyalgia rheumatica","Off-label biological therapies in patients with large vessel vasculitis and\/or polymyalgia rheumatica"],"prefix":"10.1007","volume":"77","author":[{"given":"J. C.","family":"Henes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Tony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Grunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Czihal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Proft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"325_CR1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s10067-006-0375-2","volume":"26","author":"MM Ahmed","year":"2007","unstructured":"Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM (2007) Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 26:1353\u20131355","journal-title":"Clin Rheumatol"},{"key":"325_CR2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/ard.2005.036533","volume":"64","author":"A Bhatia","year":"2005","unstructured":"Bhatia A, Ell PJ, Edwards JC (2005) Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64:1099\u20131100","journal-title":"Ann Rheum Dis"},{"key":"325_CR3","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2016.05.009","volume":"46","author":"MS Broder","year":"2016","unstructured":"Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P, Klearman M (2016) Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum 46:246\u2013252","journal-title":"Semin Arthritis Rheum"},{"key":"325_CR4","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B (2016) Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA 315:2442\u20132458","journal-title":"JAMA"},{"key":"325_CR5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10067-014-2506-5","volume":"33","author":"E Caltran","year":"2014","unstructured":"Caltran E, Di Colo G, Ghigliotti G, Capecchi R, Catarsi E, Puxeddu I, Migliorini P, Tavoni A (2014) Two takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 33:1183\u20131184","journal-title":"Clin Rheumatol"},{"key":"325_CR6","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1002\/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO;2-Y","volume":"44","author":"F Cantini","year":"2001","unstructured":"Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44:2933\u20132935","journal-title":"Arthritis Rheum"},{"key":"325_CR7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, Montecucco C, Systemic Vasculitis Study Group of the Italian Society for R (2004) Prednisone plus methotrexate for polymyalgia rheumatica: a\u00a0randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493\u2013500","journal-title":"Ann Intern Med"},{"key":"325_CR8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/1744666X.2016.1089173","volume":"12","author":"FD Carmona","year":"2016","unstructured":"Carmona FD, Martin J, Gonzalez-Gay MA (2016) New insights into the pathogenesis of giant cell arteritis and hopes for the clinic. Expert Rev Clin Immunol 12:57\u201366","journal-title":"Expert Rev Clin Immunol"},{"key":"325_CR9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1002\/art.23095","volume":"57","author":"MG Catanoso","year":"2007","unstructured":"Catanoso MG, Macchioni P, Boiardi L, Pipitone N, Salvarani C (2007) Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 57:1514\u20131519","journal-title":"Arthritis Rheum"},{"key":"325_CR10","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1136\/annrheumdis-2016-209351","volume":"75","author":"R Conway","year":"2016","unstructured":"Conway R, O\u2019Neill L, O\u2019Flynn E, Gallagher P, McCarthy GM, Murphy CC, Veale DJ, Fearon U, Molloy ES (2016) Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 75:1578\u20131579","journal-title":"Ann Rheum Dis"},{"key":"325_CR11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/art.34356","volume":"64","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, Duhaut P, Poor G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Nannini C, Cantini F, Macchioni P, Pipitone N, Del Amo M, Espigol-Frigole G, Cid MC, Martinez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazleman B, Silverman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Michet CJ, Marcus R, Gonter NJ, Maz M, Carter RE, Crowson CS, Matteson EL (2012) 2012 Provisional classification criteria for polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Arthritis Rheum 64:943\u2013954","journal-title":"Arthritis Rheum"},{"key":"325_CR12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/ard.45.2.136","volume":"45","author":"M Silva De","year":"1986","unstructured":"De Silva M, Hazleman BL (1986) Azathioprine in giant cell arteritis\/polymyalgia rheumatica: a\u00a0double-blind study. Ann Rheum Dis 45:136\u2013138","journal-title":"Ann Rheum Dis"},{"key":"325_CR13","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, Abril A, Bachta A, Balint P, Barraclough K, Bianconi L, Buttgereit F, Carsons S, Ching D, Cid M, Cimmino M, Diamantopoulos A, Docken W, Duftner C, Fashanu B, Gilbert K, Hildreth P, Hollywood J, Jayne D, Lima M, Maharaj A, Mallen C, Martinez-Taboada V, Maz M, Merry S, Miller J, Mori S, Neill L, Nordborg E, Nott J, Padbury H, Pease C, Salvarani C, Schirmer M, Schmidt W, Spiera R, Tronnier D, Wagner A, Whitlock M, Matteson EL, Dasgupta B, European League Against R, American College of R (2015) 2015 Recommendations for the management of polymyalgia rheumatica: a\u00a0European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74:1799\u20131807","journal-title":"Ann Rheum Dis"},{"key":"325_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/120638","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hetland H, Myklebust G (2013) Leflunomide as a\u00a0corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a\u00a0case series. Biomed Res Int. doi: 10.1155\/2013\/120638","journal-title":"Biomed Res Int"},{"key":"325_CR15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, Llorca J (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61:1454\u20131461","journal-title":"Arthritis Rheum"},{"key":"325_CR16","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1136\/annrheumdis-2011-200795","volume":"71","author":"PC Grayson","year":"2012","unstructured":"Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, Khalidi NA, Langford CA, Monach PA, Seo P, Warrington KJ, Ytterberg SR, Hoffman GS, Merkel PA, Vasculitis Clinical Research C (2012) Distribution of arterial lesions in Takayasu\u2019s arteritis and giant cell arteritis. Ann Rheum Dis 71:1329\u20131334","journal-title":"Ann Rheum Dis"},{"key":"325_CR17","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/S0140-6736(16)30183-0","volume":"387","author":"L Guillevin","year":"2016","unstructured":"Guillevin L, Regent A (2016) Treating giant-cell arteritis: is IL-6 the cytokine to target? Lancet 387:1882\u20131883","journal-title":"Lancet"},{"key":"325_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1\u201311","journal-title":"Arthritis Rheum"},{"key":"325_CR19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. a\u00a0randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106\u2013114","journal-title":"Ann Intern Med"},{"key":"325_CR20","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, Vasculitis Clinical Research C (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69:837\u2013845","journal-title":"Arthritis Rheumatol"},{"key":"325_CR21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/art.40037","volume":"69","author":"CA Langford","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, Seo P, Moreland LW, Weisman M, Koening CL, Sreih AG, Spiera R, McAlear CA, Warrington KJ, Pagnoux C, McKinnon K, Forbess LJ, Hoffman GS, Borchin R, Krischer JP, Merkel PA, Vasculitis Clinical Research C (2017) A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of takayasu arteritis. Arthritis Rheumatol 69:846\u2013853","journal-title":"Arthritis Rheumatol"},{"key":"325_CR22","first-page":"694","volume":"11","author":"F Liozon","year":"1993","unstructured":"Liozon F, Vidal E, Barrier J (1993) Does dapsone have a\u00a0role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheumatol 11:694\u2013695","journal-title":"Clin Exp Rheumatol"},{"key":"325_CR23","doi-asserted-by":"crossref","first-page":"e4974","DOI":"10.1097\/MD.0000000000004974","volume":"95","author":"KH Ly","year":"2016","unstructured":"Ly KH, Dalmay F, Gondran G, Palat S, Bezanahary H, Cypierre A, Fauchais AL, Liozon E (2016) Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: a single-center, retrospective study of 70 patients. Medicine (Baltimore) 95:e4974","journal-title":"Medicine (Baltimore)"},{"key":"325_CR24","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2016-210070","volume":"76","author":"C Miyabe","year":"2017","unstructured":"Miyabe C, Miyabe Y, Strle K, Kim ND, Stone JH, Luster AD, Unizony S (2017) An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis 76:898\u2013905","journal-title":"Ann Rheum Dis"},{"key":"325_CR25","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/ard.2008.093260","volume":"67","author":"ES Molloy","year":"2008","unstructured":"Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567\u20131569","journal-title":"Ann Rheum Dis"},{"key":"325_CR26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2008.088351","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study G (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68:318\u2013323","journal-title":"Ann Rheum Dis"},{"key":"325_CR27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/37.7.797","volume":"37","author":"G Pountain","year":"1998","unstructured":"Pountain G, Hazleman B, Cawston TE (1998) Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol 37:797\u2013798","journal-title":"Br J Rheumatol"},{"key":"325_CR28","unstructured":"Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kotter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester G, Dorner T (2017) Safety and efficacy of off-label biologic therapies in patients with rheumatic diseases refractory to standard of care therapy \u2013 data from a\u00a0nationwide German registry (GRAID2). Z\u00a0Rheumatol"},{"key":"325_CR29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1056\/NEJMra011913","volume":"347","author":"C Salvarani","year":"2002","unstructured":"Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N\u00a0Engl J Med 347:261\u2013271","journal-title":"N Engl J Med"},{"key":"325_CR30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/03009740500474537","volume":"35","author":"C Schaufelberger","year":"2006","unstructured":"Schaufelberger C, Mollby H, Uddhammar A, Bratt J, Nordborg E (2006) No additional steroid-sparing effect of cyclosporine a in giant cell arteritis. Scand J Rheumatol 35:327\u2013329","journal-title":"Scand J Rheumatol"},{"key":"325_CR31","first-page":"1204","volume":"68","author":"JH Stone","year":"2016","unstructured":"Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH, Collinson N (2016) Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a\u00a0phase 3, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol Suppl 68:1204\u20131205","journal-title":"Arthritis Rheumatol Suppl"},{"key":"325_CR32","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"HP Tony","year":"2011","unstructured":"Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, Haas J, Unger L, Lovric S, Haubitz M, Fischer-Betz R, Chehab G, Rubbert-Roth A, Specker C, Weinerth J, Holle J, Muller-Ladner U, Konig R, Fiehn C, Burgwinkel P, Budde K, Sorensen H, Meurer M, Aringer M, Kieseier B, Erfurt-Berge C, Sticherling M, Veelken R, Ziemann U, Strutz F, von Wussow P, Meier FM, Hunzelmann N, Schmidt E, Bergner R, Schwarting A, Eming R, Hertl M, Stadler R, Schwarz-Eywill M, Wassenberg S, Fleck M, Metzler C, Zettl U, Westphal J, Heitmann S, Herzog AL, Wiendl H, Jakob W, Schmidt E, Freivogel K, Dorner T, investigators G (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a\u00a0national registry (GRAID). Arthritis Res Ther 13:R75","journal-title":"Arthritis Res Ther"},{"key":"325_CR33","doi-asserted-by":"crossref","first-page":"912562","DOI":"10.1155\/2013\/912562","volume":"2013","author":"SH Unizony","year":"2013","unstructured":"Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, Zwerina J, Harari O, Stone JH (2013) Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013:912562","journal-title":"Int J Rheumatol"},{"key":"325_CR34","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","volume":"387","author":"PM Villiger","year":"2016","unstructured":"Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Butikofer L, Seitz M, Reichenbach S (2016) Tocilizumab for induction and maintenance of remission in giant cell arteritis: a\u00a0phase 2, randomised, double-blind, placebo-controlled trial. Lancet 387:1921\u20131927","journal-title":"Lancet"},{"key":"325_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-139-6-200309160-00015","volume":"139","author":"CM Weyand","year":"2003","unstructured":"Weyand CM, Goronzy JJ (2003) Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 139:505\u2013515","journal-title":"Ann Intern Med"},{"key":"325_CR36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2013.161","volume":"9","author":"CM Weyand","year":"2013","unstructured":"Weyand CM, Goronzy JJ (2013) Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 9:731\u2013740","journal-title":"Nat Rev Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-017-0325-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-017-0325-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T17:57:45Z","timestamp":1692813465000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-017-0325-1"}},"subtitle":["Wirksamkeits- und Sicherheitsanalyse eines nationalen Registers (GRAID2)","Safety and efficacy analysis of a nationwide German registry (GRAID2)"],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["325"],"URL":"https:\/\/doi.org\/10.1007\/s00393-017-0325-1","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}